FDA 483 OBSERVATION · #938 OF 1,932 MOST-CITED

Kits not FDA approved, specifically labeled

FDA cited this observation 19 times across 17 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Human Tissue for Transplantation19
BY FISCAL YEAR
FY20233
FY20227
FY20212
FY20202
FY20192
FY20182
FY20171

How FDA worded it — real examples

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Texas Tech University Health Sciences Center Center for Fertility and Reproductive Surgery · Lubbock, Texas · Human Tissue for Transplantation · 2023-07-26

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Cincinnati Childrens Hospital Medical Center · Cincinnati, Ohio · Human Tissue for Transplantation · 2023-07-12

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Arizona Center for Reproductive Endocrinology & Infertility · Tucson, Arizona · Human Tissue for Transplantation · 2023-06-28

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Akan Biosciences Inc · Gaithersburg, Maryland · Human Tissue for Transplantation · 2022-09-30

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Texas Tech University Health Sciences Center Center for Fertility and Reproductive Surgery · Lubbock, Texas · Human Tissue for Transplantation · 2022-09-21

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Cabell Huntington Hospital · Huntington, West Virginia · Human Tissue for Transplantation · 2022-08-18

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →